Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Kathy Lee-Sepsick
Person

Kathy Lee-Sepsick

Tracked across 2 events · 12 articles · First seen Aug 07, 2026 · Last active Aug 19, 2026

Sentiment
40
Attention
3
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
3 70
Regulatory
FDA Approves FemBloc Modular PMA Pathway
Femasys Inc. announced that the U.S. United States — Food and Drug Administration (FDA) has approved the company's modular premarket approval (PMA) pathway for FemBloc, its investigational non-surgical permanent birth control technology. This approval allows…
Impact: As CEO and Founder of Femasys, Kathy Lee-Sepsick is the public face of the company and its strategic direction. The regulatory progress under her leadership is a positive signal for the company's future.
Aug 19, 2026 · 6 articles
2 10
Business
Femasys $30M Private Placement Financing
Femasys Inc., a biomedical company developing fertility and non-surgical permanent birth control solutions, announced on August 7, 2026 that it entered into a securities purchase agreement for a $30 million private placement with accredited investors.…
Impact: Kathy Lee-Sepsick, CEO and Founder of Femasys, welcomed the financing and highlighted its importance for executing the company's business plan.
Aug 07, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Kathy Lee-Sepsick live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.